This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribas, G.
Right arrow Articles by Alcami, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribas, G.
Right arrow Articles by Alcami, A.

 Previous Article  |  Next Article 

Journal of Virology, September 2003, p. 10139-10146, Vol. 77, No. 18
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.18.10139-10146.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Genetic Variability of Immunomodulatory Genes in Ectromelia Virus Isolates Detected by Denaturing High-Performance Liquid Chromatography

Gloria Ribas,1,{dagger} Jose Rivera,2,{dagger} Margarida Saraiva,2,{ddagger} R. Duncan Campbell,1 and Antonio Alcami2*

MRC UK HGMP Resource Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SB,1 Department of Medicine and Department of Pathology, Division of Virology, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom2

Received 19 August 2002/ Accepted 26 March 2003


arrow
ABSTRACT
 
The genetic variability of nine genes in 12 isolates and strains of ectromelia virus, which causes a smallpox-like disease (mousepox) in mice, was determined and allows for classification of ectromelia viruses. The low genetic variability suggests that evolutionary pressure maintains the activity of immunomodulatory genes in natural poxvirus infections.


arrow
TEXT
 
Poxviruses are complex DNA viruses (28). Variola virus (VaV) was the causative agent of smallpox. Vaccinia virus (VV) was the vaccine agent used to eradicate smallpox (17), but VaV remains a concern because of its potential use in bioterrorism (41). Cowpox virus (CPV) is probably a rodent virus that infects other animal species. Ectromelia virus (EV) is a highly virulent natural mouse pathogen that causes mousepox, a disease that was proposed as a model of human smallpox (16, 17).

Poxviruses encode homologues of immune molecules to modulate host defense mechanisms (3, 47). The epidermal growth factor homologue VGF enhances cell proliferation, promoting virus virulence in mice (26). The complement control protein VCP blocks complement activation and inflammatory responses (23). The semaphorin homologue vSEMA interacts with a receptor in macrophages and induces cytokines and adhesion molecules (11, 46).

Other viral proteins characterized here are soluble cytokine receptors which neutralize cytokine activity (1, 27, 30, 42). VV, CPV, and EV encode soluble viral gamma interferon receptors (vIFN-{gamma}R) with unique broad species specificity (6, 29, 44). CPV encodes four soluble tumor necrosis factor receptor (vTNFR) genes, named cytokine response modifier B (crmB) (19), crmC (39), crmD (24), and crmE (36). Secreted TNF binding activity is produced by 3 of 15 VV strains due to expression of CrmC and CrmE (2, 34). crmB is the only vTNFR gene predicted to be active in VaV. crmD is active in EV isolates Moscow-3P2, MP-3, MP-4, and SF (24), whereas crmB, crmC, and crmE are truncated in EV Moscow. Another TNFR superfamily member, a secreted CD30 homologue (vCD30), has been identified in CPVs GRI-90 and Brighton Red and in EVs Hampstead and Naval (33, 37, 38). vCD30 binds CD30 ligand and has immunomodulatory activity (33, 37).

Viral immunomodulatory genes are frequently determinants of viral pathogenesis, and thus their genetic variability may shed light on their relative importance during natural infections. The expression of immunomodulatory molecules was investigated in VV strains, but the growth of VV in vitro and outside its natural host, which is unknown, may have allowed an accumulation of mutations (2, 4-7). In contrast, EV was isolated from outbreaks in laboratory mouse colonies, presumably transmitted from a natural reservoir (16, 17), and offered an excellent opportunity for these investigations. Expression of binding activity for cytokines is conserved among 12 EV isolates and strains, but genetic variability was not investigated previously (43-45).

The sequence variability of nine immunomodulatory genes in 12 EV isolates, totaling 108 genes, was investigated with a novel experimental approach used to identify single nucleotide polymorphisms in human genes. Denaturing high-performance liquid chromatography (DHPLC) subjects PCR products to ion-pair reverse-phase liquid chromatography (48). Under conditions of partial heat denaturation, heteroduplexes formed in samples having sequence variation display reduced retention times relative to their homoduplex counterparts. This identifies mutations in PCR products of unknown sequence when mixed with PCR products of known sequence. To our knowledge, this is the first report using this approach for the study of viral genes.

We studied a collection of EV isolates originated in temporally and geographically diverse laboratory mousepox outbreaks and virus strains derived from them by passage in corioallantoic membranes (43). These included EV Hampstead (1930), the first EV to be isolated (25); isolates from German and Austrian outbreaks (EVs MP-1, MP-2, MP-3, MP-4, and MP-5) (32); and EV Naval, isolated in the United States (12). We also analyzed the plaque-purified EV strain Moscow-3P2 (10), derived from the highly virulent EV Moscow (1947) (8); Ishibashi-I-111, originated in Japan (20); and two egg-passaged derivatives of EV Hampstead, EVs Hampstead Egg (15) and Mill Hill (17). EV Hampstead Egg and EV Ishibashi-I-111 are attenuated in mice after footpad inoculation (16, 17).

Sequence information on EV genes is very limited (9, 16). EV VGF, VCP, and vSEMA genes were PCR amplified by use of oligonucleotides based on the VV sequence and were sequenced on both strands on an Applied Biosystems 377 sequencer (Perkin Elmer). The VGF gene in EV Moscow-3P2 encodes a truncated polypeptide that lacks the transmembrane anchoring domain (Fig. 1A). VGF is shed from the cell by proteolytic cleavage (26). Myxoma virus encodes a truncated VGF that is secreted and active (26); thus, the EV VGF may also be active. The VCP gene in EV Moscow-3P2 encodes a full-length polypeptide (18) (Fig. 1B). Consistent with this, supernatants from EV-infected cultures block the classical and alternative pathways of complement activation (J. Rivera and A. Alcami, unpublished data). EV Moscow-3P2 vSEMA was previously expressed for functional studies, but its sequence was not reported (11). We found that the vSEMA gene encodes a polypeptide of similar length to that from VV Copenhagen and longer than that from VV WR (18, 40) (Fig. 1C).



View larger version (62K):
[in this window]
[in a new window]
  		FIG. 1. Predicted amino acid sequence of the EV homologues of VGF, VCP, and vSEMA. Shown are pairwise alignments of the predicted amino acid sequences of VGF (A), VCP (B), and vSEMA (C) from EV Moscow-3P2 and VV Copenhagen (18). Solid backgrounds represent amino acid differences and stars indicate stop codons. Solid triangles show signal peptide cleavage sites (SP). In the VGF sequence (A), the regions of higher sequence similarity to host EGF are underlined and the transmembrane anchoring domain is double underlined.

DHPLC analysis was carried out with an automated system from TransGenomic (Crewe, United Kingdom) (35). Viral genes were PCR amplified as overlapping fragments of <500 bp (13) with specific oligonucleotides (Table 1), Taq DNA polymerase, and 10 to 50 ng of viral core DNA (14). PCR products were mixed 1:1 with DNA from a reference EV, denatured at 95°C for 5 s, cooled to 65°C over 40 min, and loaded onto a preheated reverse-phase column based on nonporous poly(styrene-divinyl-benzene) particles (SNASep column; TransGenomic). PCR products were eluted through an acetonitrile gradient in 0.1 M triethylamine acetate buffer, pH 7, at 0.9 ml/min and were detected at 260 nm. The temperature for detection of heteroduplexes was deduced from both computational analysis (WaveMaker software; Transgenomic) and an experimental melting profile of the reference DNA. PCR samples of unknown sequence were mixed with the control DNA and run at two to four different temperatures to increase the probability of detecting mismatches that may not resolve at some temperatures due to domains with very different GC content.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Sequences of the oligonucleotides used in these studies

The chromatograms of the reference strain (Moscow-3P2 or Hampstead) consisted of a single major peak at most temperatures tested, unless some denaturation occurred which broadened the peak (Fig. 2). The chromatograms were different when the reference DNA was mixed with PCR fragments from other viruses containing mutations which were detected at some but not all temperatures. To determine the accuracy of the DHPLC analysis, the DNA sequences of all the genes were determined for five EVs (Moscow-3P2, Hampstead, Naval, MP-5, and Ishibashi-I-111) and of those genes predicted by DHPLC analysis to have mutations for the other EVs.




View larger version (78K):
[in this window]
[in a new window]
  		FIG. 2. DHPLC and sequence analysis of EV genes. The genes were PCR amplified under the following conditions: 30 cycles consisting of 95°C for 1 min, the indicated annealing temperature for 1 min, and 72°C for 1 min, followed by 72°C for 10 min. The PCR fragments were mixed with the reference DNA and subjected to DHPLC analysis. Elution profiles associated with the DHPLC analysis of PCR fragments from the indicated genes are shown. x and y axes depict retention times in minutes after injection and intensity of UV fluorescence at 260 nm, respectively. The fragment number (F) and melting temperature used (T) are indicated, with an asterisk marking those melting temperatures for which mutations were detected. The reference EV used for each gene is shown in parentheses. The results obtained with the reference DNA alone and when it was mixed with DNA from viruses that showed no sequence variation are labeled "EV isolates." The results from those DNA fragments in which mutations were detected are represented. The base change and the position number of the base affected are given for each chromatogram for samples containing mutations. The presence of multiple mutations (MM), insertions (Ins), and deletions ({Delta}) is indicated.

The DHPLC analysis showed no mutations in the vIFN-{gamma}R gene among EV isolates (Fig. 2), consistent with the conservation of secreted IFN-{gamma} binding activity (44). Mutations in the vSEMA gene were only identified in EV Hampstead Egg, which had a truncated polypeptide (Fig. 2 and 3). More genetic variability was found in the VCP gene (Fig. 2 and 3). The sequence of the EV Ishibashi-I-111 gene was the most divergent from that of the reference strain EV Moscow-3P2, and interestingly was almost identical to that of VV Copenhagen (18). Two point mutations in the VCP gene of EV Ishibashi-I-111 (G681A and A717C) result in two amino acid substitutions (D231N and K239N) compared to VCP encoded by VV Copenhagen. This was unlikely to be due to PCR or viral DNA contamination since it was confirmed in two different preparations of EV Ishibashi-I-111 DNA, and parallel amplification of a control gene showed the expected EV sequence (not shown). The VGF gene was identical in all EVs except for Naval and MP-5 (Fig. 2). The mutations translated into amino acid substitutions but retained the shorter polypeptide length of EV VGF (Fig. 3).



View larger version (67K):
[in this window]
[in a new window]
  		FIG. 3. Variability of genes encoded by EV isolates and strains. The number of fragments analyzed for each EV gene is shown in brackets. The genes that are predicted from sequence analysis to be active or for which biological activity has been demonstrated are indicated with one or two asterisks, respectively. The variability at the DNA level is marked ({surd}), with the fragment shown in parentheses. Mutations and deletions (2) introduced in the amino acid sequence are indicated. All genes were analyzed by DHPLC, and those that were also sequenced are indicated with a shaded cell.

All EVs tested express secreted TNF binding activity (43). CrmB was found to be truncated in EV Moscow-3P2 due to a deletion (24). The length of the PCR products amplified from all EVs indicated a similar deletion (not shown), and DHPLC analysis showed genetic variability in EVs Naval and MP-4 (Fig. 2 and 3). CrmC was also found to be truncated in EV Moscow-3P2 due to mutations (24), and DHPLC analysis indicated identical sequences in all EVs tested (Fig. 2). CrmD was previously identified as an active vTNFR in EV, and the sequence of the crmD gene was reported for EVs Moscow-3P2, MP-3, and MP-4 (24). DHPLC analysis showed that the most divergent gene was encoded by EV Naval (Fig. 2 and 3), and mutations were detected in that of EV MP-5. Mutations in the crmD gene encoded by EVs MP-3 and MP-4 have been identified (24), but they were not detected by DHPLC. DNA sequencing confirmed the absence of mutations in our isolates (not shown). The crmE gene encodes a truncated 81-amino-acid polypeptide in EVs Hampstead and Moscow (36), and the DHPLC analysis showed high conservation among the EV genomes (Fig. 2). Mutations in the vCD30 gene were detected in EVs Naval, Ishibashi-I-111, and Mill Hill, but only that in EV Naval translated into an amino acid substitution (Fig. 2 and 3).

Figure 3 summarizes the genetic variability of nine genes in 12 EVs. The results predicted by the DHPLC analysis in 108 genes were confirmed by DNA sequencing of 52 genes. The immunomodulatory genes are well conserved. The EV isolates that showed more variability when compared to EV Moscow-3P2 or Hampstead were Naval, Ishibashi-I-111, MP-5, and Hampstead Egg. The most variable genes were those encoding vCD30 and VCP.

We examined the sensitivity and specificity of DHPLC and concluded that DHPLC offers a reliable approach for the detection of genetic variability in viral genomes, providing the following advantages: (i) automation following temperature optimization, (ii) no requirement for special primers, (iii) no need for purification of PCR products, (iv) running time of 5 min per sample, and (v) low cost. This technique needs to be combined with DNA sequencing to determine the nature of the mutation, but initial DHPLC analysis reduces the need to sequence all samples. Here we illustrate that DHPLC analysis of 108 EV genes indicated only 13 genes that presented mutations relative to a reference gene.

Most mutations were detected by using the optimal melting temperature (Tm) suggested by the WaveMaker software, in agreement with Jones et al. (21), who described that Tm and Tm + 2°C are sufficient to detect point mutations. Only the presence of multiple melting domains of Tm at >4°C apart requires that more temperatures be used. This was the case for 5 of 18 fragments for this study. This problem may be easily avoided by dividing the gene into smaller fragments with more homogeneous melting temperatures. No correlation of DHPLC profiles with mutation type was observed. This is expected since the degree of denaturation depends on the nature of both the mismatched and flanking sequences (22, 31).

The EV immunomodulatory genes encoded by EV isolates are highly conserved and the mutations do not translate into major amino acid changes (Fig. 3). A mutation in the vSEMA gene of EV Hampstead Egg was the only one that inactivated the gene. Expression of secreted binding activity for interleukin-18 (IL-18), IL-1ß, TNF, chemokines, IFN-{gamma}, and IFN-{alpha}/ß is highly conserved among EV isolates and strains (43-45). The only exceptions were the lack of IL-18 binding protein in EVs Ishibashi-I-111 and Hampstead Egg and of chemokine binding activity in EV Mill Hill. EVs Hampstead Egg and Mill Hill were derived from EV Hampstead by serial passage in chorioallantoic membranes. This may have allowed the introduction of mutations and caused the attenuation of EV Hampstead Egg in mice (16, 17). The only immunomodulatory gene inactivated in EV isolates was the IL-18 binding protein encoded by EV Ishibashi-I-111, a virus that is attenuated after footpad inoculation (16, 17). This suggests that there is strong selective pressure to keep these genes active in natural EV infections.

This study sheds light on the evolutionary origin of EV isolates, which is largely unknown (16). EVs isolated from London, Central Europe, or Moscow had identical sequences, with the exception of minor differences in EVs MP-4 and MP-5. The EV isolate from Japan, Ishibashi-I-111, is closely related to the European isolates, with the exception of the VCP gene, which suggests recombination with a VV-related poxvirus. The most divergent virus is EV Naval, which was isolated from a 1995 outbreak in the Naval Medical Research Institute (Bethesda, Md.) that was initiated after inoculation of mice with a contaminated commercially prepared mouse serum of U.S. origin (12). The United States is considered free of mousepox, and the outbreaks in the United States have been traced to the importation of infected mice or mouse tissue from Europe (49). We show that EV Naval is unrelated to the European EV isolates and therefore may have originated elsewhere, consistent with the suggestion that EV-infected mice exist in the United States (12).

In conclusion, the analysis of EV genetic variability by DHPLC combined with DNA sequencing has enabled us to investigate the presence of mutations in 108 EV genes and to determine the evolutionary relationship among EV isolates. We provide a detailed characterization of genetic variability in a poxvirus that has not been passaged extensively in tissue culture. The high conservation of immunomodulatory genes among EV isolates suggests the presence of evolutionary pressure to keep these genes active in natural poxvirus infections.

Nucleotide sequence accession numbers. The GenBank accession numbers for the sequences reported in this paper are as follows: CD30 gene (four EV isolates), AJ567675 to AJ567678; CrmB gene (five EV isolates), AJ567679 to AJ567683; CrmC gene (five EV isolates), AJ567684 to AJ567687 and AJ567726; CrmD gene (seven EV isolates), AJ567688 to AJ567693 and AJ567727; CrmE gene (three EV isolates), AJ567694 to AJ567696; vIFN-{gamma}R (four EV isolates), AJ574797 to AJ574800; SEMA gene (six EV isolates), AJ574801 to AJ574806; VCP gene (seven EV isolates), AJ574807 to AJ574813; and VGF gene (five EV isolates), AJ574814 to AJ574818.


arrow
ACKNOWLEDGMENTS
 
G.R., J.R., and M.S. contributed equally to this work and are shown in alphabetical order.

This project was funded by the Medical Research Council, the Wellcome Trust (grant 051087/Z97/Z), and the European Union. G.R. was funded in part by a postdoctoral fellowship from the European Union. M.S. is funded by Fundacao para a Ciencia e Tecnologia-Praxis XXI (grant BD-18081/98). A.A. is a Wellcome Trust Senior Research Fellow.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Level 5, Box 157, Hills Rd., Cambridge CB2 2QQ, United Kingdom. Phone: 44 (1223) 763403. Fax: 44 (1223) 330158. E-mail: aa258{at}mole.bio.cam.ac.uk. Back

{dagger} Present address: Centro Nacional de Investigaciones Oncológicas, 28029 Madrid, Spain. Back

{ddagger} Present address: National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. Back


arrow
REFERENCES
 
    1
  1. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.[CrossRef][Medline]
    2. 2
  2. Alcami, A., A. Khanna, N. L. Paul, and G. L. Smith. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-959.[Abstract]
    3. 3
  3. Alcami, A., and U. H. Koszinowski. 2000. Viral mechanisms of immune evasion. Immunol. Today 21:447-455.[CrossRef][Medline]
    4. 4
  4. Alcami, A., and G. L. Smith. 1996. Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Trends Microbiol. 4:321-326.[CrossRef][Medline]
    5. 5
  5. Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.[CrossRef][Medline]
    6. 6
  6. Alcami, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639.[Abstract]
    7. 7
  7. Alcami, A., J. A. Symons, P. D. Collins, T. J. Williams, and G. L. Smith. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-633.[Abstract/Free Full Text]
    8. 8
  8. Andrewes, C. H., and W. J. Elford. 1947. Infectious ectromelia: experiments on interference and immunisation. Br. J. Exp. Pathol. 28:278-285.
    9. 9
  9. Chen, N., R. M. Buller, E. M. Wall, and C. Upton. 2000. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox. Virus Res. 66:155-173.[CrossRef][Medline]
    10. 10
  10. Chen, W., R. Drillien, D. Spehner, and R. M. Buller. 1992. Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 187:433-442.[CrossRef][Medline]
    11. 11
  11. Comeau, M. R., R. Johnson, R. F. DuBose, M. Petersen, P. Gearing, T. VandenBos, L. Park, T. Farrah, R. M. Buller, J. I. Cohen, L. D. Strockbine, C. Rauch, and M. K. Spriggs. 1998. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 8:473-482.[CrossRef][Medline]
    12. 12
  12. Dick, E. J., Jr., C. L. Kittell, H. Meyer, P. L. Farrar, S. L. Ropp, J. J. Esposito, R. M. Buller, H. Neubauer, Y. H. Kang, and A. E. McKee. 1996. Mousepox outbreak in a laboratory mouse colony. Lab. Anim. Sci. 46:602-611.[Medline]
    13. 13
  13. Ellis, L. A., C. F. Taylor, and G. R. Taylor. 2000. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum. Mutat. 15:556-564.[CrossRef][Medline]
    14. 14
  14. Esposito, J., R. Condit, and J. Obijeski. 1981. The preparation of orthopoxvirus DNA. J. Virol. Methods 2:175-179.[CrossRef][Medline]
    15. 15
  15. Fenner, F. 1949. Studies in mousepox (infectious ectromelia of mice). VI. A comparison of the virulence and infectivity of three strains of ectromelia virus. Aust. J. Exp. Biol. Med. Sci. 27:31-43.[Medline]
    16. 16
  16. Fenner, F., and R. M. L. Buller. 1997. Mousepox, p. 535-553. In N. Nathanson (ed.), Viral pathogenesis. Lippincott-Raven, Philadelphia, Pa.
    17. 17
  17. Fenner, F., R. Wittek, and K. R. Dumbell. 1989. The orthopoxviruses. Academic Press, Inc., London, United Kingdom.
    18. 18
  18. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266, 517-563.[CrossRef][Medline]
    19. 19
  19. Hu, F., C. A. Smith, and D. J. Pickup. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343-356.[CrossRef][Medline]
    20. 20
  20. Ichihashi, Y., and S. Matsumoto. 1966. Studies on the nature of Marchal bodies (A-type inclusion) during ectromelia virus infection. Virology 29:264-275.[CrossRef][Medline]
    21. 21
  21. Jones, A. C., J. Austin, N. Hansen, B. Hoogendoorn, P. J. Oefner, J. P. Cheadle, and M. C. O'Donovan. 1999. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin. Chem. 45:1133-1140.[Abstract/Free Full Text]
    22. 22
  22. Ke, S. H., and R. M. Wartell. 1993. Influence of nearest neighbour sequence on the stability of base pair mismatches in long DNA: determination by temperature-gradient gel electrophoresis. Nucleic Acids Res. 21:5137-5143.[Abstract/Free Full Text]
    23. 23
  23. Kotwal, G. J. 2000. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol. Today 21:242-248.[CrossRef][Medline]
    24. 24
  24. Loparev, V. N., J. M. Parsons, J. C. Knight, J. F. Panus, C. A. Ray, R. M. Buller, D. J. Pickup, and J. J. Esposito. 1998. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Natl. Acad. Sci. USA 95:3786-3791.[Abstract/Free Full Text]
    25. 25
  25. Marchal, J. 1930. Infectious ectromelia. A hitherto undescribed virus disease of mice. J. Pathol. Bacteriol. 33:713-728.[CrossRef]
    26. 26
  26. McFadden, G. 1995. Poxvirus growth factor, p. 17-27. In G. McFadden (ed.), Viroceptors, virokines and related immune modulators encoded by DNA viruses. R. G. Landes Co., Austin, Tex.
    27. 27
  27. McFadden, G., and P. M. Murphy. 2000. Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr. Opin. Microbiol. 3:371-378.[CrossRef][Medline]
    28. 28
  28. Moss, B. 2001. Poxviridae: the viruses and their replication, p. 2849-2883. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott Williams and Wilkins, Philadelphia, Pa.
    29. 29
  29. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.[CrossRef][Medline]
    30. 30
  30. Nash, P., J. Barrett, J. X. Cao, S. Hota-Mitchell, A. S. Lalani, H. Everett, X. M. Xu, J. Robichaud, S. Hnatiuk, C. Ainslie, B. T. Seet, and G. McFadden. 1999. Immunomodulation by viruses: the myxoma virus story. Immunol. Rev. 168:103-120.[CrossRef][Medline]
    31. 31
  31. O'Donovan, M. C., P. J. Oefner, S. C. Roberts, J. Austin, B. Hoogendoorn, C. Guy, G. Speight, M. Upadhyaya, S. S. Sommer, and P. McGuffin. 1998. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics 52:44-49.[CrossRef][Medline]
    32. 32
  32. Osterrieder, N., H. Meyer, and M. Pfeffer. 1994. Characterization of the gene encoding the A-type inclusion body protein of mousepox virus. Virus Genes 8:125-135.[CrossRef][Medline]
    33. 33
  33. Panus, J. F., C. A. Smith, C. A. Ray, T. D. Smith, D. D. Patel, and D. J. Pickup. 2002. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc. Natl. Acad. Sci. USA 99:8348-8353.[Abstract/Free Full Text]
    34. 34
  34. Reading, P. C., A. Khanna, and G. L. Smith. 2002. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 292:285-298.[CrossRef][Medline]
    35. 35
  35. Ribas, G., M. J. Neville, and R. D. Campbell. 2001. Single-nucleotide polymorphism detection by denaturing high-performance liquid chromatography and direct sequencing in genes in the MHC class III region encoding novel cell surface molecules. Immunogenetics 53:369-381.[CrossRef][Medline]
    36. 36
  36. Saraiva, M., and A. Alcami. 2001. CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J. Virol. 75:226-233.[Abstract/Free Full Text]
    37. 37
  37. Saraiva, M., P. Smith, P. G. Fallon, and A. Alcami. 2002. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196:829-839.[Abstract/Free Full Text]
    38. 38
  38. Shchelkunov, S. N., P. F. Safronov, A. V. Totmenin, N. A. Petrov, O. I. Ryazankina, V. V. Gutorov, and G. J. Kotwal. 1998. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 243:432-460.[CrossRef][Medline]
    39. 39
  39. Smith, C. A., F. Q. Hu, T. D. Smith, C. L. Richards, P. Smolak, R. G. Goodwin, and D. J. Pickup. 1996. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. Virology 223:132-147.[CrossRef][Medline]
    40. 40
  40. Smith, G. L., Y. S. Chan, and S. T. Howard. 1991. Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat. J. Gen. Virol. 72:1349-1376.[Abstract/Free Full Text]
    41. 41
  41. Smith, G. L., and G. McFadden. 2002. Science and society. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527.[CrossRef][Medline]
    42. 42
  42. Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcami. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154.[CrossRef][Medline]
    43. 43
  43. Smith, V. P., and A. Alcami. 2000. Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J. Virol. 74:8460-8471.[Abstract/Free Full Text]
    44. 44
  44. Smith, V. P., and A. Alcami. 2002. Inhibition of interferons by ectromelia virus. J. Virol. 76:1124-1134.[Abstract/Free Full Text]
    45. 45
  45. Smith, V. P., N. A. Bryant, and A. Alcami. 2000. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J. Gen. Virol. 81:1223-1230.[Abstract/Free Full Text]
    46. 46
  46. Spriggs, M. K. 1999. Shared resources between the neural and immune systems: semaphorins join the ranks. Curr. Opin. Immunol. 11:387-391.[CrossRef][Medline]
    47. 47
  47. Tortorella, D., B. E. Gewurz, M. H. Furman, D. J. Schust, and H. L. Ploegh. 2000. Viral subversion of the immune system. Annu. Rev. Immunol. 18:861-926.[CrossRef][Medline]
    48. 48
  48. Underhill, P. A., L. Jin, A. A. Lin, S. Q. Mehdi, T. Jenkins, D. Vollrath, R. W. Davis, L. L. Cavalli-Sforza, and P. J. Oefner. 1997. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res. 7:996-1005.[Abstract/Free Full Text]
    49. 49
  49. Whitney, R. A. 1974. Ectromelia in United States mouse colonies. Science 184:609.[Free Full Text]

Journal of Virology, September 2003, p. 10139-10146, Vol. 77, No. 18
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.18.10139-10146.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fedele, C. G., Negredo, A., Molero, F., Sanchez-Seco, M. P., Tenorio, A. (2006). Use of Internally Controlled Real-Time Genome Amplification for Detection of Variola Virus and Other Orthopoxviruses Infecting Humans. J. Clin. Microbiol. 44: 4464-4470 [Abstract] [Full Text]  
  • Esteban, D. J., Buller, R. M. L. (2005). Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86: 2645-2659 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribas, G.
Right arrow Articles by Alcami, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribas, G.
Right arrow Articles by Alcami, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»